Selatogrel is an investigational drug currently undergoing Phase 3 clinical trials. It has not been approved for use in any country.

Viatris and/or Idorsia does not make, and expressly disclaims, any representations or warranties of any kind, either express or implied (including, without limitation, any implied warranties of content or non-infringement) with regard to any such information disseminated through this program/presentation/poster, including its accuracy and/or completeness. The viewers assume all risk for use of the information and the content provided in this program/presentation/poster. In no event shall Viatris and/or Idorsia or any of its affiliates, directors, employees, officers, consultants and service providers be liable, directly or indirectly, for any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; whether or not the user has been informed of the possibility in advance; and whether or not resulting from or in connection with the creation or use of or reliance upon the program/presentation/poster.